Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole
- 1 January 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 47 (8), 533-542
- https://doi.org/10.2165/00003088-200847080-00003
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyJournal of Psychopharmacology, 2006
- Effectiveness of aripiprazole v. Haloperidol in acute bipolar maniaThe British Journal of Psychiatry, 2005
- Development and validation of an LC–MS/MS method for the quantitative determination of aripiprazole and its main metabolite, OPC-14857, in human plasmaJournal of Chromatography B, 2005
- Pharmacokinetics, Tolerability, and Safety of Aripiprazole following Multiple Oral Dosing in Normal Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophreniaInternational Journal of Neuropsychopharmacology, 2003
- A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar ManiaAmerican Journal of Psychiatry, 2003
- Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective DisorderArchives of General Psychiatry, 2003
- Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsSchizophrenia Research, 2003
- Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placeboSchizophrenia Research, 2000
- Superiority of the Child-Pugh Classification to Quantitative Liver Function Tests for Assessing Prognosis of Liver CirrhosisScandinavian Journal of Gastroenterology, 1989